Home Newsfeeds JMP Securities Downgrades iBio to Market Perform

JMP Securities Downgrades iBio to Market Perform

JMP Securities analyst Roy Buchanan downgrades iBio (AMEX:IBIO) from Market Outperform to Market Perform.

byBenzinga Newsdesk

February 16, 2023

1 minute read

JMP Securities analyst Roy Buchanan downgrades iBio (AMEX:IBIO) from Market Outperform to Market Perform.

Analyst Ratings

Expert Ratings for Crocs

By Benzinga Insights

November 28, 9:00 AM

Crocs (NASDAQ:CROX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

CROX

ImmunoGen’s Newly Approved Ovarian Cancer Drug Listed As Preferred Regime

By Vandana Singh

December 28, 1:56 PM

The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which include ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) as a preferred regimen.

IMGN

Paylocity Sees Q4 Revenue $299.2M-$303.2M Vs $300.17M Est.; FY23 Revenue $1.165B-$1.169B Vs $1.16B Est.

By Happy Mohamed

May 4, 4:33 PM

Business Outlook Based on information available as of May 4, 2023, Paylocity is issuing guidance for the fourth quarter and full fiscal year 2023 as indicated

PCTY

Harpoon Therapeutics, Inc. Files Prospectus For The Offering and Resale Of 25,751,025 shares of Common Stock Shares Of Common Stock By Selling Stockholders

By Benzinga Newsdesk

December 8, 5:12 PM

This prospectus covers the offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 25,751,025 shares of our common stock, which consists of (i) 12,805,350 shares of our common

HARP

JMP Securities Downgrades iBio to Market Perform

Related Posts

Expert Ratings for Crocs

ImmunoGen’s Newly Approved Ovarian Cancer Drug Listed As Preferred Regime

Paylocity Sees Q4 Revenue $299.2M-$303.2M Vs $300.17M Est.; FY23 Revenue $1.165B-$1.169B Vs $1.16B Est.

Harpoon Therapeutics, Inc. Files Prospectus For The Offering and Resale Of 25,751,025 shares of Common Stock Shares Of Common Stock By Selling Stockholders